In vivo neutralization of tumor necrosis factor attenuates the generalized Shwartzman reaction in the rabbit

Journal of Endotoxin Research

Volumn 3, Issue 1, 1996, Pages 67-75

  Ueda, Yoshihiko ^a   Lee, Kwang Hoon ^a   Ito, Shogo ^a   Saito, Kenichi ^a   Niesen, Neal ^a   Brentjens, Jan R ^a   Gans, Reinold O B ^a,b  

^a UNIVERSITY AT BUFFALO   (United States)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G; LIPOPOLYSACCHARIDE; NEUTRALIZING ANTIBODY; POLYCLONAL ANTIBODY; TUMOR NECROSIS FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATTENUATION; CONTROLLED STUDY; GENE EXPRESSION REGULATION; GRAM NEGATIVE BACTERIUM; NONHUMAN; RABBIT; SEPSIS; SHWARTZMAN PHENOMENON;

ANIMALIA; BACTERIA (MICROORGANISMS); CAPRA HIRCUS; NEGIBACTERIA; ORYCTOLAGUS CUNICULUS;

EID: 0029984428     PISSN: 09680519     EISSN: None     Source Type: Journal    
DOI: 10.1177/096805199600300108     Document Type: Article

References (47)

1. Pinsky M.R., Vincent J.L., Deviere J., Alegre M, Kahn R.J., Dupont E. Serum cytokine levels in human septic shock - relation to multiple-system organ failure and mortality. Chest 1993; 103: 565-575.
2. Mathison J.C., Wolfson E., Ulevitch R.J. Participation of tumor necrosis factor in the mediation of gram negative bacterial lipopolysaccharide-induced injury in rabbits. J Clin Invest 1988; 81: 1925-1937.
3. Waage A., Espevik T., Habtensen A. Association between tumor necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet 1988; ii: 355-357.
4. Tracey K., Lowry S., Cerami A. Cachectin/TNF-alpha in septic shock and septic adult respiratory distress syndrome. Am Rev Respir Dis 1988; 138: 1377-1379.
5. Tracey K., Beutler B., Lowry S. et al. Shock and tissue injury induced by recombinant human cachectin. Science 1986; 234: 470-474.
6. Beutler B., Milsark I.W., Cerami A.C. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 1985; 228: 869-871.
7. Hjort P.F., Rapaport S.I. The Shwartzman reaction: pathogenetic mechanisms and clinical manifestations. Annu Rev Med 1967; 16: 135.
8. Mueller-Berghaus G. Pathophysiologic and biochemical events in disseminated intravascular coagulation: dysregulation of procoagulant and anticoagulant pathways. Semin Thromb Hemost 1989; 15: 58-87.
9. Cotran R.S., Pober J.S. Effects of cytokines on vascular endothelium: their role in vascular and immune injury. Kidney Int 1989; 35: 969-975.
10. Herbert J.M., Savi P., Laplace M.C. et al. IL-4 and IL-13 exhibit comparable abilities to reduce pyrogen-induced expression of procoagulant activity in endothelial cells and monocytes. FEBS Lett 1993; 328: 268-270.
11. Bevilacqua M.P., Pober J.S., Majeau G.R., Fiers W., Cotran R.S., Gimbrone M.A. Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin-1. Proc Natl Acad Sci USA 1986; 83: 4533-4537.
12. De Boer J.P., Creasy A.A., Chang A. et al. Activation patterns of coagulation and fibrinolysis in baboons following infusion with lethal or sublethal dose of Escherichia coli. Circ Shock 1993; 39: 59-67.
13. Conkling P., Greenberg C., Weinberg J. Tumor necrosis factor induces tissue factor-like activity in human leukemia cell line U937 and peripheral blood monocytes. Blood 1988; 72: 128-133.
14. Wiggins R.C., Njoku N., Sedor J.R. Tissue factor production by cultured rat mesangial cells. Stimulation by TNFα and lipopolysaccharide. Kidney Int 1990; 37: 1281-1285.
15. Camussi G., Bussolino F., Salvidio G., Baglioni C. Tumor necrosis factor/cachectin stimulates peritoneal macrophages, polymorphonuclear neutrophils, and vascular endothelial cells to synthesize and release platelet-activating factor. J Exp Med 1987; 166: 1390-1404.
16. Van der Poll T, Buller H.R., Ten Cate H. et al. Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Engl J Med 1990; 322: 1622-1627.
17. Fiedler V.B., Loof I., Sander E., Voehringer V., Galanos C., Fournel M.A. Monoclonal antibody to tumor necrosis factor-α prevents lethal endotoxin sepsis in adult rhesus monkeys. J Lab Clin Med 1992; 120: 574-588.
18. Emerson T.E., Lindsey D.C., Jesmok G.J., Duerr M.L., Fournel M.A. Efficacy of monoclonal antibody against tumor necrosis factor alpha in an endotoxemic baboon model. Circ Shock 1992; 38: 75-84.
19. Hinshaw L.B., Tekamp-Olson P., Chang A.C.K. et al. Survival of primates in LD100 septic shock following therapy with antibody to tumor necrosis factor (TNFα). Circ Shock 1990; 30: 279-292.
20. Van der Poll T, Levi M., Van Deventer S.J.H. et al. Differential effects of anti-tumor necrosis factor monoclonal antibodies on systemic inflammatory responses in experimental endotoxemia in chimpanzees. Blood 1994; 83: 446-451.
21. Thomas L, Good R.A. Studies on the generalized Shwartzman reaction I. General observations concerning the phenomenon. J Exp Med 1952; 96: 605-625.
22. McKay D.G. Vessel wall and thrombogenesis - endotoxin. Thromb Diathes Haemorrh 1973; 29: 11-26.
23. Warr T.A., Rao L.V.M., Rapaport S.I. Disseminated intravascular coagulation in rabbits induced by administration of endotoxin or tissue factor: effect of anti-tissue factor antibodies and measurement of plasma extrinsic pathway inhibitor activity. Blood 1990; 75: 1481-1489.
24. Brukman J., Wiggins R.C. Procoagulant activity in kidneys of normal and bacterial lipopolysaccharide-treated rabbits. Kidney Int 1987; 32: 31-38.
25. Gans R.O.B., DiPirro J.C., Ueda Y., Niesen N., Lee K.H., Brentjens J.R. The effect of SRI 63-675, a competitive platelet-activating factor receptor-antagonist, in the generalized Shwartzman reaction. J Lipid Mediat Cell Signal 1994; 10: 229-242.
26. Andres G.A., Accinni L, Beiser S.M. et al. Localization of fluorescein-labelled anti-nucleoside antibodies in glomeruli of patients with active systemic lupus erythematosus nephritis. J Clin Invest 1970; 49: 2106-2118.
27. Compton S.J., Jones G.G. Mechanism of dye response and interference in the Bradford protein assay. Anal Biochem 1985; 151: 369-374.
28. Yam LT, Li C.Y., Crosby W.H. Cytochemical identification of monocytes and granulocytes. Am J Clin Pathol 1971; 55: 283-290.
29. Li C.Y., Lam K.W., Yam L.T. Esterases in human leukocytes. J Histochem Cytochem 1973; 21: 1-12.
30. Cybulsky M.I., Chan M.K.W., Movat H.Z. Acute inflammation and microthrombosis induced by endotoxin, interleukin-1, and tumor necrosis factor and their implication in gram-negative infection. Lab Invest 1988; 58: 365-378.
31. Jesmok G., Lindsey C., Duerr M., Fournel M., Emerson T. Efficacy of monoclonal antibody against human recombinant tumor necrosis factor in E. coli-challenged swine. Am J Pathol 1992; 141: 1197-1207.
32. Miserez R., Jungi T.W. Lps-induced, but not interferon-gamma-induced procoagulant activity of suspended human macrophages is followed by a refractory state of low procoagulant expression. Thromb Res 1992; 65: 733-744.
33. Silva A.T., Appelmelk B.J., Buurman W.A., Bayston K.P., Cohen J. Monoclonal antibody to endotoxin core protects mice from Escherichia coli sepsis by a mechanism independent of tumor necrosis factor and interleukin-6. Infect Dis 1990; 162: 454-459.
34. Sheppard B.C., Norton J.A. Tumor necrosis factor and interleukin-1 protection against the lethal effects of tumor necrosis factor. Surgery 1991; 109: 698-705.
35. McCall C.E., Grossowilmoth L.M., Larue K., Guzman R.N., Cousart S.L. Tolerance to endotoxin-induced expression of the interleukin-1beta gene in blood neutrophils of humans with the sepsis syndrome. J. Clin Invest 1993; 91: 853-861.
36. Fahmi H., Chaby R. Selective refractoriness of macrophages to endotoxin-induced production of tumor necrosis factor, elicited by an autocrine mechanism. J Leukocyte Biol 1993; 53: 45-52.
37. Etheredge E.E., Spitzer J.A. Chronic endotoxemia reversibly alters respiratory burst activity of circulating neutrophils. J Surg Res 1993; 55: 261-268.
38. Cochrane C.G. The enhancement of inflammatory injury. Am Rev Respir Dis 1987; 136: 1-2.
39. Eskandari M.K., Bolgos G., Miller C., Nguyen D.T., DeForge L.E., Remick D.G. Anti-tumor necrosis factor antibody therapy fails to prevent lethality after cecal ligation and puncture or endotoxemia. J immunol 1992; 148: 2724-2730.
40. Echtenacher B., Falk W., Mannel D.N., Krammer RH. Requirement of endogenous tumor necrosis factor/cachectin for recovery from experimental peritonitis. J Immunol 1990; 145: 3762-3766.
41. Franks A.K., Kujawa K.I., Yaffe L.J. Experimental elimination of tumor necrosis factor in low-dose endotoxin models has variable effects on survival. Infect Immun 1991; 59: 2609-2614.
42. Fomsgaard A., Holder I.A. Effect of a human IgG preparation rich in antibodies to a wide range of lipopolysaccharides on Gram-negative bacterial sepsis in burned mice. APMIS 1993; 101: 229-234.
43. Desouza V.R., Kaveri S.V., Kazatchkine M.D. Intravenous immunoglobulin (IVIg) in the treatment of autoimmune and inflammatory diseases. Clin Exp Rheumatol 1993; 11: S33-S36.
44. Kindt G.G., Moore S.A., She Z., Wewers M.D. Endotoxin priming of monocytes augments Fc-gamma receptor cross-linking-induced TNF-alpha and IL-1-beta release. Am J Physiol 1993; 265: L178-L185.
45. Svenson M., Hansen M.B., Bendtzen K. Binding of cytokines to pharmaceutically prepared human immunoglobulin. J Clin Invest 1993; 92: 2533-2539.
46. DiPirro J.C., Hom J., Ueda Y. et al. TNF does not mediate the generalized Shwartzman reaction in the absence of polymorphonuclear leukocytes. Eur Cytokine Netw 1992; 3: 193 (Abstract).
47. Carlsen E., Flatmark A., Prydz H. Cytokine-induced procoagulant activity in monocytes and endothelial cells. Transplantation 1988; 46: 575-580.